ArticleKidney medicine2026
Chinese Herb-Induced Type II Crescentic Glomerulonephritis: A Case Report of Four Patients.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced type II crescentic glomerulonephritis is an uncommon but severe renal syndrome, rarely linked to pharmaceutical agents, with no established association to Chinese herbal medicines to date. In this case report, we described 4 patients who developed biopsy-confirmed type II crescentic glomerulonephritis within 1-4 weeks following exposure to Chinese herbal products. Key histopathologic findings included crescent formation in ≥50% of glomeruli and immunofluorescence demonstrating granular mesangial deposits of immunoglobulin G and C3, accompanied by prominent acute tubulointerstitial injury. Clinically, 75% of cases presented with macroscopic hematuria, reflecting severe glomerular capillary damage. The therapeutic regimen comprised intravenous methylprednisolone, cyclophosphamide, and plasma exchange. Persistent hematuria and a longer duration of drug exposure were associated with slower and incomplete renal recovery during follow-up. Our case report suggested that Chinese herbal medicine may be a potential environmental trigger for crescentic glomerulonephritis and highlight the value of clinical inquiry into herbal product use in cases of rapidly progressive glomerulonephritis. Further toxicovigilance and compound-specific risk assessments are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.